<DOC>
	<DOCNO>NCT00002339</DOCNO>
	<brief_summary>To determine safety , toleration , efficacy fluconazole oral suspension treatment esophageal candidiasis immunocompromised patient , include AIDS .</brief_summary>
	<brief_title>A Study Fluconazole Treatment Fungal Infections Throat Patients With Weakened Immune Systems</brief_title>
	<detailed_description>Patients receive fluconazole oral suspension minimum 3 week maximum 8 week . Patients evaluated weekly , treatment continue 2 week resolution symptom . Endoscopic exams possibly biopsy perform baseline end treatment . Patients undergo follow-up 2 week post-treatment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Inclusion Criteria Patients must : AIDS immunocompromising condition . Candidal esophagitis . Life expectancy least 2 month . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Evidence noncandidal systemic fungal infection . Abnormalities may preclude esophagoscopy endoscopy . Unable tolerate fluconazole . Unable give inform consent . Enrollment experimental trial approve nonapproved drug systemic compound ( unless approve Pfizer Clinical Monitor ) . Other condition would make patient unsuitable enrollment . Concurrent Medication : Excluded : Concomitant oral topical antifungal agent . Other experimental medication . Patients follow prior condition exclude : History allergy imidazole azoles . Prior Medication : Excluded : Any oral topical antifungal therapy within past 3 day . Active use illicit illegal drug .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Esophagitis</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Candidiasis</keyword>
	<keyword>Immunocompromised Host</keyword>
</DOC>